APL-2
APL2-304
Phase 3 small_molecule completed
Quick answer
APL-2 for Geographic Atrophy is a Phase 3 program (small_molecule) at Apellis Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Apellis Pharmaceuticals
- Indication
- Geographic Atrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed